Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
NCT06601101 · University of Campinas, Brazil · PHASE3 · terminated · last registry update 2026-11-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Enrollment closed before the planned 36 eyes were reached because of the limited number of eligible patients and the long recruitment period (July 2024 to December 2025); 20 eyes of 19 participants were enrolled.” | – | Registry record, University of Campinas, Brazil |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-3167 + insulin degludec (NCT07913061)
- 2026-08-31Results posted on the registry: Emory University, Oral Anti-diabetes Drugs alone + Basal bolus insulin (NCT04416269)
- 2026-08-31Also stopped (terminated): Emory University, Oral Anti-diabetes Drugs alone + Basal bolus insulin (NCT04416269)
- 2026-08-26Results posted on the registry: Sling Therapeutics, Inc., Linsitinib + Placebo (NCT05276063)
- 2026-08-07Phase 3 first posted: Sling Therapeutics, Inc., linsitinib + Placebo (NCT07753603)
- 2026-07-02Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT06340854)
- 2026-06-03Results posted on the registry: Novo Nordisk A/S, Insulin Icodec + Semaglutide (NCT05813912)
- 2026-04-30Results posted on the registry: Novo Nordisk A/S, Insulin Icodec (NCT05823948)
- 2026-04-16Phase 3 first posted: Radboud University Medical Center, Intranasal insulin-40U + Intranasal sodium chloride 0.9% (NCT07532577)
- 2026-04-14Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR33 Injection + Insulin Degludec Injection (Tresiba®) (NCT07527078)
- 2026-03-04Results posted on the registry: University of Virginia, a drug against INSR (NCT06111508)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision